Egg Donor Recruitment: Messaging and Handoffs

By FertileRank™ · Sources checked and content updated September 20, 2026. Marketing and operational guidance for clinic and ART business teams; not clinical or legal advice.

Organize the page around the questions a prospective donor needs answered: who operates the program, what the next contact involves, where to find reviewed information about time commitments and procedures, and how screening decisions are made. Use language that supports a considered choice rather than pressure.

Check the page with the team receiving inquiries. If marketing says “apply in minutes” but the next step is a lengthy clinical questionnaire, explain that distinction. A visitor should not have to submit sensitive information just to understand the program’s basic process.

ASRM’s 2021 ethics opinion supports compensation for donors’ time, inconvenience and discomfort while cautioning against undue inducement. It does not turn a marketing headline into a universal compensation standard. ASRM: financial compensation of oocyte donors, 2021 ethics opinion.

Publish only program-approved amounts, conditions and reimbursement explanations. State material qualifications beside the claim. Avoid invented deadlines, guaranteed acceptance or suggestions that payment reflects the value of a person’s genetics. Do not use financial urgency as a substitute for explaining the commitment.

ASRM’s 2024 donation guidance addresses clinical screening and evaluation. Use it as a source for the qualified program reviewer, not as permission for a marketing team to create its own eligibility rules. ASRM: gamete and embryo donation guidance, 2024.

• Use an initial contact route appropriate to the program’s approved data requirements.
• Move health histories, testing information and sensitive screening into the approved clinical system.
• Explain what will happen after the first contact and who will respond.
• Give the person a way to ask questions before proceeding.
• Keep advertising tags and general marketing reports away from unreviewed screening details.

Review the audience, geography, creative and destination together before a campaign starts. Confirm current platform policies for the exact activity; an available targeting control is not evidence that its use is permitted. Avoid copy that assumes a person’s health status or exploits an inferred vulnerability.

For content-led discovery, answer practical program questions with a named review owner and links to the organization’s authoritative information. Original explanations of the process are more useful than repeating a generic eligibility list across many city pages.

Use agreed aggregate measures such as valid interest requests, delivery to the correct program team and unresolved process questions. Clinical acceptance is a separate decision and should not be treated as a promise from the advertisement.

If many visitors abandon the next step, investigate whether the page accurately described it. Review the message and transition with operations before increasing acquisition volume. Keep reporting focused on process improvement without exposing donor identities or sensitive screening outcomes.

• Review the inquiry handoff
• Plan marketing governance
• Explore donor-program marketing support

• ASRM: financial compensation of oocyte donors, 2021 ethics opinion
• ASRM: gamete and embryo donation guidance, 2024

Policy and practice guidance can change. Check the linked primary source before implementing a material change. Examples and suggested workflows are FertileRank recommendations, not documented client results. How this library is prepared.